Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab + nab-paclitaxel + gemcitabine for resectable or borderline resectable pancreatic cancer
ChiCTR2200064424Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and gemcitabine in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: 2-year overall survival rate and progression-free survival. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2200064424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064424.